💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Amrutanjan Health Care Limited is an India-based company, which is engaged in the business of manufacturing, supplying and sale of products in pain management, congestion management, beverages, and hygiene and services in pain management. Its segments include OTC Products,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, trading cheap versus its own history.
Amrutajan Health is scored on the pharma / healthcare framework. It keeps a healthy 11.1% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.62×) — worth a closer look. Free cash flow is worth about 1.0% of its market value.
Over the last 3 years revenue compounded at 10%/yr and profit at 13%/yr. Book value has grown 8%/yr. Return on equity is a healthy 17.1%. In the latest quarter profit fell 73% versus the prior quarter.
At 26× earnings, the stock sits at the 7th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~12%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 25.9 | — | — |
| P/B | 3.87 | 4.11 | better |
| EV/EBITDA | 17.32 | 19.15 | better |
| ROE | 17.07 | — | — |
| ROCE | 22.68 | 6.87 | better |
| ROA | 11.12 | — | — |
| Quick Ratio | 2.02 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 10% CAGR — growing but slowly.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (13% vs 10%) — margin expansion is at work.
Operating margins have been stable around 15% — no major structural shift.
ROE at 16% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 14% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 31% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (31% spread) — likely seasonality, lumpy orders, or project-based revenue.
Profit fell 73% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (11% → 4%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 46.5% — dispersed ownership; institutional flows drive the stock. MF stake down 3.9pp — domestic funds are booking profits or rebalancing out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.